MARTA- Non-interventional observational study to document the efficacy and tolerability of taxanes (Docetaxel, Paclitaxel) in treatment against operable, nodal-positive and locally advanced metastatic mamma carzinoma

MARTA- Non-interventional observational study to document the efficacy and tolerability of taxanes (Docetaxel, Paclitaxel) in treatment against operable, nodal-positive and locally advanced metastatic mamma carzinoma - MARTA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00007183

Enrollment

600

Registered

2014-11-06

Start date

2014-12-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50 D70

Interventions

Group 1: Efficacy and safety profile of docetaxel axios, axitaxel will be documented under routine practice conditions in patients where treatment with docetaxel axios, axitaxel is indicated. No furth

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: - Signed and dated consent is available - The treatment decision was made independently of a possible inclusion in the study - Patient is not at the same time a clinical trial participant - Patient is at least 18 years old.

Exclusion criteria

Exclusion criteria: - Contraindications to the use of Axiplatin according to the SmPC. - Current therapy was started more than 12 weeks ago. - The patient is concurrently participating in a clinical trial. - Pregnancy is present or the patient is breastfeeding.

Design outcomes

Primary

Measure	Time frame
Efficacy and tolearability in routine practice	—

Secondary

Measure	Time frame
Side effects which were not reported so far	—

Countries

Germany

Contacts

Public ContactJulia Farchmin

AxioNovo Gmbh

farchmin@axionovo.de+49 521 988350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026